About the Company
We do not have any company description for Poseida Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Poseida Therapeutics, Inc.
2024-11-26 | Poseida Therapeutics, Inc. Announces Agreement to be ...
SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated ...
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche ...
Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4 ...
Poseida Therapeutics, Inc. Announces Agreement to be Acquired ... - Nasdaq
--Poseida Therapeutics, Inc., a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare ...
Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA ...
Poseida’a open-label, multicenter, single ascending dose, Phase 1 study will assess the safety of P-BCMA-101 in up to 40 subjects with relapsed and/or refractory multiple myeloma.
Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You ...
Over the past quarter, shares of Poseida Therapeutics, Inc. Have risen 25.34%, and are up 76.67% in the last year. On the other hand, the S&P 500 has only moved 12.69% and 37.58%, respectively.
Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week ... - Nasdaq
Over the past quarter, shares of Poseida Therapeutics, Inc. Have risen 25.34%, and are up 76.67% in the last year. On the other hand, the S&P 500 has only moved 12.69% and 37.58%, respectively.
Poseida stock drops more than 30% as prostate cancer drug trial halted ...
Poseida Therapeutics Inc. shares dropped in the extended session Monday as the biotech drug maker announced a safety trial for a prostate cancer drug had been halted because of a patient death.
Similar Companies
Loading the latest forecasts...